BR122013033954B8 - novos esteróides apresentando solubilidade em água e resistência contra metabolismo aumentadas, e métodos para sua produção - Google Patents

novos esteróides apresentando solubilidade em água e resistência contra metabolismo aumentadas, e métodos para sua produção

Info

Publication number
BR122013033954B8
BR122013033954B8 BR122013033954A BR122013033954A BR122013033954B8 BR 122013033954 B8 BR122013033954 B8 BR 122013033954B8 BR 122013033954 A BR122013033954 A BR 122013033954A BR 122013033954 A BR122013033954 A BR 122013033954A BR 122013033954 B8 BR122013033954 B8 BR 122013033954B8
Authority
BR
Brazil
Prior art keywords
methods
production
water solubility
resistance against
exhibiting water
Prior art date
Application number
BR122013033954A
Other languages
English (en)
Portuguese (pt)
Other versions
BR122013033954B1 (pt
Inventor
Ragagnin Gianna
Bäckström Torbjörn
Original Assignee
Umecrine Ab
Umecrine Cognition Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Umecrine Ab, Umecrine Cognition Ab filed Critical Umecrine Ab
Publication of BR122013033954B1 publication Critical patent/BR122013033954B1/pt
Publication of BR122013033954B8 publication Critical patent/BR122013033954B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR122013033954A 2006-11-21 2007-11-20 novos esteróides apresentando solubilidade em água e resistência contra metabolismo aumentadas, e métodos para sua produção BR122013033954B8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86065806P 2006-11-21 2006-11-21
US60/860,658 2006-11-21
PCT/SE2007/050876 WO2008063128A1 (fr) 2006-11-21 2007-11-20 Utilisation de stéroïdes dérivés du prégnane et de l'androstane pour la fabrication d'une composition pharmaceutique pour le traitement de troubles du snc
BRPI0718945A BRPI0718945B8 (pt) 2006-11-21 2007-11-20 novos esteróides apresentando solubilidade em água e resistência contra metabolismo aumentadas, e métodos para sua produção

Publications (2)

Publication Number Publication Date
BR122013033954B1 BR122013033954B1 (pt) 2021-01-12
BR122013033954B8 true BR122013033954B8 (pt) 2021-05-25

Family

ID=39429970

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122013033954A BR122013033954B8 (pt) 2006-11-21 2007-11-20 novos esteróides apresentando solubilidade em água e resistência contra metabolismo aumentadas, e métodos para sua produção
BRPI0718945A BRPI0718945B8 (pt) 2006-11-21 2007-11-20 novos esteróides apresentando solubilidade em água e resistência contra metabolismo aumentadas, e métodos para sua produção

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0718945A BRPI0718945B8 (pt) 2006-11-21 2007-11-20 novos esteróides apresentando solubilidade em água e resistência contra metabolismo aumentadas, e métodos para sua produção

Country Status (16)

Country Link
US (9) US8580983B2 (fr)
EP (4) EP2711371B1 (fr)
JP (5) JP5386362B2 (fr)
AU (1) AU2007322423C1 (fr)
BR (2) BR122013033954B8 (fr)
CA (2) CA2664126C (fr)
DK (3) DK2792681T3 (fr)
ES (3) ES2662500T3 (fr)
HU (3) HUE036410T2 (fr)
IN (1) IN2014DN02014A (fr)
MX (1) MX2009005335A (fr)
PL (3) PL2711371T3 (fr)
PT (1) PT2097437E (fr)
RU (1) RU2458065C2 (fr)
SI (1) SI2097437T1 (fr)
WO (1) WO2008063128A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2792681T3 (en) 2006-11-21 2017-01-23 Umecrine Ab Use of Pregnancy and Androstan Steroids in the Preparation of a Pharmaceutical Composition for the Treatment of CNS Disorders.
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
US20120322781A1 (en) 2010-01-14 2012-12-20 Umecrine Mood Ab Pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties
EP2566482A1 (fr) * 2010-05-07 2013-03-13 Institut National de la Santé et de la Recherche Médicale Antagonistes du récepteur de la progestérone et utilisations correspondantes
BR112015012194B8 (pt) * 2012-11-28 2022-11-22 Univ Bordeaux Derivados éter-benzil-3-(4'-substituídos) de pregnenolona
ES2886506T3 (es) 2013-03-13 2021-12-20 Sage Therapeutics Inc Esteroides neuroactivos
MX2016008851A (es) * 2014-01-29 2017-03-23 Umecrine Cognition Ab Compuesto esteroideo para su uso en el tratamiento de encefalopatia hepatica.
SI3224269T1 (sl) * 2014-11-27 2020-10-30 Sage Therapeutics, Inc. Sestavki in metode za zdravljenje CNS motenj
TWI748936B (zh) * 2015-01-12 2021-12-11 瑞典商優鎂奎認知Ａｂ公司 新穎化合物
HUE055199T2 (hu) 2015-07-06 2021-11-29 Sage Therapeutics Inc Oxiszterolok és alkalmazási eljárásaik
DE102015120587A1 (de) 2015-11-26 2017-06-01 Brandenburgische Technische Universität Cottbus-Senftenberg Verfahren zur selektiven Oxygenierung von Testosteron und Testosteron-ähnlichen Steroiden
SI3436022T1 (sl) 2016-04-01 2022-08-31 Sage Therapeutics, Inc. Oksisteroli in postopki za uporabo le-teh
WO2017193046A1 (fr) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxystérols et méthodes d'utilisation associées
US10278977B2 (en) 2016-06-06 2019-05-07 Umecrine Cognition Ab Methods for treating hypersomnolence
EP3529256B1 (fr) 2016-10-18 2023-08-09 Sage Therapeutics, Inc. Oxystérols et leurs procédés d'utilisation
TWI815800B (zh) 2016-10-18 2023-09-21 美商賽吉醫療公司 氧固醇(oxysterol)及其使用方法
KR102478510B1 (ko) 2017-02-10 2022-12-16 아사리나 파마 아베 의학적 치료에서 사용하기 위한 3-베타-히드록시-5-알파-프레그난-20-온
EP3579842A4 (fr) 2017-02-10 2020-12-23 Asarina Pharma AB 3-bêta-hydroxy-5-alpha-prégnan-20-one destinée à être utilisée dans le traitement des tremblements essentiels
BR112020010519A2 (pt) 2017-11-27 2020-10-20 Umecrine Cognition Ab formulação farmacêutica de oxima de 3¿lfa-etinil-3¿eta-hidroxiandrostan-17-ona
WO2019193138A1 (fr) 2018-04-05 2019-10-10 Asarina Pharma Aps Antagonistes de gaba-a pour traiter des troubles de sevrage de substance
CN112457362B (zh) * 2019-09-06 2023-09-19 上海青东生物科技有限公司 一种卤代四环三萜衍生物及其制备与应用
EP4079307A1 (fr) 2021-04-20 2022-10-26 Umecrine Cognition AB Nouvelle utilisation médicale
EP4430056A1 (fr) 2021-11-10 2024-09-18 Umecrine AB Stéroïdes 3?-hydroxy, 3?-éthyle pour la modulation du sous-type ?3 du récepteur gaba-a
CN118251403A (zh) 2021-11-10 2024-06-25 梅克芳股份公司 用于调节GABA-A受体的α-3亚型的3.α.取代的3.β.-羟基17-肟化的雄甾烷化合物
EP4429669A1 (fr) 2021-11-10 2024-09-18 Umecrine AB Stéroïde utilisé en tant que modulateur du récepteur gabaa
EP4389129A1 (fr) 2022-12-22 2024-06-26 Umecrine Cognition AB Oxime de 3a-éthynyl-3bêta-hydroxyandrostan 17-one pour le traitement de la maladie de parkinson et de la dyskinésie induite par l-dopa

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1463755A (fr) * 1960-01-26 1966-07-22 Nouveaux stéroïdes de la série de l'androstane et leur procédé de préparation
US3152121A (en) * 1962-03-16 1964-10-06 Upjohn Co 20-ketals of 3-hydroxy-5 beta-pregnan-20-one
CH491889A (de) * 1966-10-22 1970-06-15 Richter Gedeon Vegyeszet Verfahren zur Herstellung von Steroiden
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5234603A (en) 1991-06-04 1993-08-10 Analytical Development Corporation Methods employing a zirconium salt for use in wastewater treatment
EP0701444B1 (fr) * 1993-05-24 2010-04-07 Purdue Pharma Ltd. Procedes et compositions induisant le sommeil
ES2296594T3 (es) * 1994-02-14 2008-05-01 Euro-Celtique S.A. Androstanos y pregnanos para la modulacion alosterica del receptor de gaba.
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
KR100394548B1 (ko) * 1994-11-23 2004-02-05 퍼듀 파머 리미티드 Gaba수용체의알로스테릭조절을위한안드로스탄및프레그난계열화합물
DE69634039T2 (de) * 1995-06-06 2005-12-08 Euro-Celtique S.A. Steroidderivate der Androstan- und der Pregnanreihe
WO1998005337A1 (fr) * 1996-08-01 1998-02-12 Cocensys, Inc. Utilisation de ligands de recepteurs gaba et nmda pour le traitement des cephalees de la migraine
ATE307592T1 (de) 1998-03-11 2005-11-15 Torbjoern Backstroem Epiallopregnanolon zur behandlung von krankheiten des cns
AU3467699A (en) * 1998-04-14 1999-11-01 Pharmadigm, Inc. Method for reducing central nervous system impairment
US20030060425A1 (en) * 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
CZ294278B6 (cs) * 1999-11-25 2004-11-10 Ústav organické chemie a biochemie AV ČR Neuroaktivní steroidy a způsob jejich přípravy
GB2363984A (en) 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
GB2363983A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 7-hydroxyepiandrosterone
FR2831441B1 (fr) * 2001-10-25 2003-12-26 Oreal Utilisation cosmetique de derives de la dhea
EP1310258A1 (fr) * 2001-11-08 2003-05-14 Etienne-Emile Baulieu Enantiomères de stéroides pour l'augmentation de la mémoire et de la fonction cognitive
SE0104423D0 (sv) 2001-12-27 2001-12-27 Umecrine Ab Pregnane steroids and their use in the treatment of CNS disorders
BRPI0518359A2 (pt) * 2004-11-18 2008-11-18 Umecrine Ab antagonistas de gaba-esteràide e seu uso para tratamento de distérbios do snc
DK2792681T3 (en) 2006-11-21 2017-01-23 Umecrine Ab Use of Pregnancy and Androstan Steroids in the Preparation of a Pharmaceutical Composition for the Treatment of CNS Disorders.
EP2566482A1 (fr) 2010-05-07 2013-03-13 Institut National de la Santé et de la Recherche Médicale Antagonistes du récepteur de la progestérone et utilisations correspondantes

Also Published As

Publication number Publication date
CA2833976C (fr) 2016-03-15
US8580983B2 (en) 2013-11-12
AU2007322423B2 (en) 2013-01-10
EP2097437B1 (fr) 2015-05-27
EP2711371A1 (fr) 2014-03-26
PL2792681T3 (pl) 2017-06-30
AU2007322423A1 (en) 2008-05-29
US20140011792A1 (en) 2014-01-09
US20130102578A1 (en) 2013-04-25
US20130102579A1 (en) 2013-04-25
JP2013177411A (ja) 2013-09-09
EP2711372A1 (fr) 2014-03-26
JP2013173781A (ja) 2013-09-05
EP2711371B1 (fr) 2018-01-10
BRPI0718945B8 (pt) 2021-05-25
RU2458065C2 (ru) 2012-08-10
CA2833976A1 (fr) 2008-05-29
US20150315231A1 (en) 2015-11-05
CA2664126C (fr) 2014-04-29
HUE033037T2 (hu) 2017-11-28
BRPI0718945B1 (pt) 2020-10-13
US20140011793A1 (en) 2014-01-09
JP5386362B2 (ja) 2014-01-15
ES2607852T3 (es) 2017-04-04
US20080119416A1 (en) 2008-05-22
DK2711371T3 (en) 2018-04-16
US8853190B2 (en) 2014-10-07
US20130281421A1 (en) 2013-10-24
WO2008063128A1 (fr) 2008-05-29
US20140011779A1 (en) 2014-01-09
DK2097437T3 (en) 2015-06-29
ES2543841T3 (es) 2015-08-24
JP2013173782A (ja) 2013-09-05
PT2097437E (pt) 2015-09-15
EP2792681A1 (fr) 2014-10-22
AU2007322423C1 (en) 2013-08-15
JP2015147774A (ja) 2015-08-20
US20160272670A1 (en) 2016-09-22
BR122013033954B1 (pt) 2021-01-12
PL2097437T3 (pl) 2015-12-31
JP2010510210A (ja) 2010-04-02
MX2009005335A (es) 2009-06-08
IN2014DN02014A (fr) 2015-07-10
SI2097437T1 (sl) 2015-10-30
US9200028B2 (en) 2015-12-01
DK2792681T3 (en) 2017-01-23
EP2097437A1 (fr) 2009-09-09
BRPI0718945A2 (pt) 2013-12-24
BRPI0718945A8 (pt) 2017-09-19
PL2711371T3 (pl) 2018-06-29
JP5918170B2 (ja) 2016-05-18
ES2662500T3 (es) 2018-04-06
EP2792681B1 (fr) 2016-10-19
JP5657052B2 (ja) 2015-01-21
RU2009107537A (ru) 2010-12-27
CA2664126A1 (fr) 2008-05-29
HUE026961T2 (en) 2016-07-28
EP2097437A4 (fr) 2012-12-26
HUE036410T2 (hu) 2018-07-30

Similar Documents

Publication Publication Date Title
BR122013033954B8 (pt) novos esteróides apresentando solubilidade em água e resistência contra metabolismo aumentadas, e métodos para sua produção
WO2007103719A3 (fr) MODULATEURS DE LA 11-β-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE DE TYPE 1, LEURS COMPOSITIONS PHARMACEUTIQUES ET LEURS PROCÉDÉS D'UTILISATION
WO2007067504A3 (fr) Composes lactames et procedes d'utilisation de ceux-ci
MX360301B (es) Moleculas pequeñas que contienen boro como agentes antiinflamatorios.
CL2008003407A1 (es) Compuestos derivados de aril- y heteroarilcarbonilo de heterobiciclo sustituido; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento y/o prevencion de trastornos metabolicos, mediado por la inhibicion de la enzima hsd-1.
WO2007038138A3 (fr) Utilisation pharmaceutique de composes amido
MX2009006823A (es) Formas de dosificacion solidas de desintegracion oral que comprenden progestina y metodos para hacer y usar las mismas.
MX2009009428A (es) Analogos de ciclopamina heterociclicos y metodos de uso de los mismos.
SG151329A1 (en) Amido compounds and their use as pharmaceuticals
EA201101270A1 (ru) Циклические ингибиторы 11бета-гидроксистероид дегидрогеназы 1
BRPI0710485B1 (pt) composições líquidas úteis no tratamento de doenças respiratórias
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
MY155418A (en) Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
MX349787B (es) Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de ácido.
UA91848C2 (ru) Применение соединений диосметина в лечении и предотвращении тромботическим патологиям
WO2008005303A3 (fr) Modulateurs de trpv1 à base de thiazolopyrimidine
BRPI0817028A2 (pt) composto inibidor de diacilglicerol acil tranferase, composição farmacêutica que o contém, uso do composto, métodos para o tratamento ou profilaxia de diabetes, obesidade, distúrbios de alimentação e dislidemias e diabetes do tipo ii
TW200942549A (en) Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1
MX2007011493A (es) Modalidades antiinflamatorias.
CL2008000982A1 (es) Compuestos derivados de 5-oxo-isoxazol-carboxamida; proceso de preparacion; composicion farmaceutica; procedimiento de produccion de la composicion farmaceutica; y uso en el tratamiento y/o prevencion de trastornos ateroscleroticos, de metabolismo de
MX2010001822A (es) Azepina- y diazepina-sulfonamidas sustituidas utiles para inhibir 11beta-hidroxiesteroide deshidrogenasa tipo-1.
MX2009004142A (es) Metodo para prevenir o tratar sindrome metabolico.
BRPI0810997A2 (pt) Composto, pró-droga, composição farmacêutica, método para prevenir ou tratar distúrbio do sono em um mamífero, e, uso do composto
BRPI0818822A2 (pt) Forma amorfa de um composto anti-inflamatório
WO2007108004A3 (fr) Derives du s-alkylisothiouronium pour le traitement de maladies inflammatoires

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: UMECRINE COGNITION AB (SE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/11/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: MANUTENCAO DA EXTINCAO - ART. 78 INCISO IV DA LPI